NEXGEL, Inc. (NXGL) Earnings Call Transcripts

NEXGEL, Inc.'s Latest Earnings Call - Q1 FY2026

In the first quarter of 2026, NEXGEL, Inc. reported revenue of $2.65 million, down from $2.81 million year-over-year, indicating a flat performance primarily due to lower sales from the Silly George brand. Management highlighted the recent acquisition of BioNX, which is expected to triple annual revenue to approximately $35 million and be immediately accretive to profitability. The company has raised $13.8 million to support this acquisition and ongoing operations, and guidance for the second quarter includes anticipated normalization of Silly George sales and initial contributions from BioNX.

Reported metrics

Guidance from management

Management expects normalization of Silly George sales in Q2 and anticipates initial revenue contributions from the BioNX acquisition, which is projected to triple annual revenue to approximately $35 million.

What management said

Yes, it is. We don't expect it to stay flat. Silly George had an uncharacteristically bad fourth quarter and kind of a meh first quarter year-over-year, down a little bit. So we see already a recovery in April on that product line. So we think there'll be some growth, but we were kind of modest in that. We have very little growth built in for this particular segment.

So we probably have added and our CFO, Ian, is on the call as well. So correct me if I'm mistaken in this, Ian. But I think that we've added -- in fact, why don't I just ask you what we think the operating overhead is?

What analysts pressed on

Analysts expressed concerns regarding the flat performance of the legacy business, particularly the Silly George brand, and the impact of operating expenses on profitability. There were also questions about the timeline for revenue generation from the BioNX products and the effectiveness of the sales strategy.

Main topics on the call

• Acquisition of BioNX — NEXGEL's acquisition of BioNX is expected to significantly enhance its revenue potential, with management stating, 'On a pro forma basis, we anticipate it to approximately triple our annual revenue to roughly $35 million...
• Revenue Performance — The company's revenue for Q1 2026 was $2.65 million, a decrease from $2.81 million in Q1 2025. Management noted that sales from Silly George were lower, but there was growth in contract manufacturing and the MEDAGEL bran...
• Cash Position and Funding — NEXGEL reported cash and restricted cash of approximately $2.1 million as of March 31, 2026, with a current cash balance of $1.8 million. The company raised $13.8 million to fund the BioNX acquisition and working capital...
• Sales Strategy for BioNX — Management indicated that the sales force for BioNX is just beginning to ramp up, stating, 'We're really just getting started' with sales efforts. This suggests a cautious but optimistic outlook for future revenue contri...

Read the full NEXGEL, Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 17 NEXGEL, Inc. earnings call transcripts on record, spanning March 27, 2023 to May 15, 2026. Based on this history, NEXGEL, Inc. reports quarterly. The most recent call on file is dated May 15, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

NXGL

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

17

First call

March 27, 2023

Most recent

May 15, 2026

Reporting cadence

quarterly